A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma

IntroductionBispecific antibodies (BsAbs) are novel immunotherapy agents for the treatment of relapsed/refractory multiple myeloma (RRMM). Currently, 3 BsAbs (teclistamab, talquetamab, and elranatamab) are approved for the treatment of RRMM. Administering BsAbs in different practice settings is cruc...

Full description

Saved in:
Bibliographic Details
Main Authors: Alfred L. Garfall, Rahul Banerjee, Laurent Frenzel, Cyrus Khandanpour, Yi Lin, Erica Ottoni, Robert Rifkin, Sarah Rockwell, Cesar Rodriguez, Humberto Villefort, Elena Zamagni
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
bispecific antibodies
bispecifics
outpatient
teclistamab
talquetamab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1630146/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1630146/full

Similar Items